INOVIO to Present at Upcoming Scientific Conference

Rhea-AI Summary

INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines, has announced its participation in the upcoming Orphan Drug Summit in Boston, Massachusetts. The company will present on July 16 at 4:30 PM ET, focusing on their DMAb Technology and its transformational potential in rare disease treatment.

The presentation will explore the capabilities of next generation DNA medicine technology in addressing rare diseases, as part of a conference that brings together industry leaders and innovators to discuss technological and manufacturing advancements in the rare disease space.

News Market Reaction – INO

+0.75%

+0.75% Session move

In the trading session that priced this news, INO gained 0.75%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PLYMOUTH MEETING, Pa., July 7, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be presenting on the potential of next generation DNA medicine technology in rare disease at the upcoming Orphan Drug Summit in Boston, Massachusetts. The conference brings together industry leaders and innovators in the rare disease space to explore the latest developments in technology and manufacturing.

Orphan Drug Summit
Boston, MA
Date: July 16
Time: 4:30-4:55pm ET
Presentation: DMAb Technology: The Transformational Potential of Next Gen DNA Medicine in Rare Disease

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-scientific-conference-302499023.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

When is INOVIO (INO) presenting at the Orphan Drug Summit 2025?

INOVIO will present on July 16, 2025, from 4:30 to 4:55 PM ET at the Orphan Drug Summit in Boston, MA.

What will INOVIO present at the Orphan Drug Summit 2025?

INOVIO will present on their DMAb Technology and its transformational potential for next generation DNA medicine in rare disease treatment.

Where can I watch INOVIO's Orphan Drug Summit 2025 presentation?

The press release does not specify viewing options. Interested parties should contact INOVIO's investor relations for information about accessing the presentation.

What is INOVIO's main business focus?

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases.